Taro Pharmaceutical Industries (NYSE:TARO) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a report issued on Saturday. The firm set a “strong-buy” rating on the stock.

Separately, HC Wainwright lowered Taro Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $43.00 target price on the stock. in a research report on Thursday, January 18th.

Taro Pharmaceutical Industries Stock Down 0.2 %

TARO opened at $42.40 on Friday. Taro Pharmaceutical Industries has a 52-week low of $24.69 and a 52-week high of $45.76. The company has a market cap of $1.59 billion, a P/E ratio of 34.75 and a beta of 0.61. The firm’s 50-day moving average price is $42.14 and its 200-day moving average price is $40.06.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings data on Thursday, January 25th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.26. The firm had revenue of $157.15 million for the quarter, compared to the consensus estimate of $154.90 million. Taro Pharmaceutical Industries had a net margin of 7.48% and a return on equity of 3.26%. On average, research analysts anticipate that Taro Pharmaceutical Industries will post 1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Taro Pharmaceutical Industries

A number of large investors have recently bought and sold shares of TARO. Allspring Global Investments Holdings LLC purchased a new stake in Taro Pharmaceutical Industries in the 3rd quarter worth approximately $65,000. PenderFund Capital Management Ltd. purchased a new stake in Taro Pharmaceutical Industries in the 4th quarter worth approximately $92,000. Strs Ohio boosted its position in Taro Pharmaceutical Industries by 58.8% in the 3rd quarter. Strs Ohio now owns 2,700 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Taro Pharmaceutical Industries in the 4th quarter worth approximately $105,000. Finally, SG Americas Securities LLC purchased a new stake in Taro Pharmaceutical Industries in the 3rd quarter worth approximately $141,000. Hedge funds and other institutional investors own 91.40% of the company’s stock.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.